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AbsTrACT
Objectives we aimed to identify existing outcome 
measures for functional neurological disorder (FND), to 
inform the development of recommendations and to 
guide future research on FND outcomes.
Methods A systematic review was conducted to 
identify existing FND- specific outcome measures and 
the most common measurement domains and measures 
in previous treatment studies. Searches of embase, 
MeDLiNe and PsyciNFO were conducted between 
January 1965 and June 2019. The findings were 
discussed during two international meetings of the FND- 
Core Outcome Measures group.
results Five FND- specific measures were identified—
three clinician- rated and two patient- rated—but their 
measurement properties have not been rigorously 
evaluated. No single measure was identified for use 
across the range of FND symptoms in adults. Across 
randomised controlled trials (k=40) and observational 
treatment studies (k=40), outcome measures most often 
assessed core FND symptom change. Other domains 
measured commonly were additional physical and 
psychological symptoms, life impact (ie, quality of life, 
disability and general functioning) and health economics/
cost–utility (eg, healthcare resource use and quality- 
adjusted life years).
Conclusions There are few well- validated FND- specific 
outcome measures. Thus, at present, we recommend that 
existing outcome measures, known to be reliable, valid and 
responsive in FND or closely related populations, are used 
to capture key outcome domains. increased consistency 
in outcome measurement will facilitate comparison of 
treatment effects across FND symptom types and treatment 
modalities. Future work needs to more rigorously validate 
outcome measures used in this population.
INTrOduCTION
Functional neurological disorder (FND or conver-
sion disorder) is defined by motor and sensory 
symptoms (eg, tremor, dystonia, limb weakness, 
numbness and seizures) that demonstrate clinical 
features incompatible with other neurological/
medical diagnoses and that are associated with 
significant distress and functional impairment.1–3 
Until recently, there were few controlled treat-
ment trials and little research effort into outcome 
measurement in FND. However, there has been a 
marked increase in the number and quality of inter-
vention studies, so it is now critical to optimise 
outcome measures for this population, to facil-
itate comparison of the effectiveness and efficacy 
of different treatment modalities for specific FND 
symptoms.
FND has features that make decisions regarding 
outcome measurement particularly complex.4 5 
These include heterogeneity and variability of symp-
toms and the marked influence of attention, beliefs 
and expectations.6–8 Discrepancy between objec-
tive measures and patients’ subjective experiences 
of symptoms can also be a prominent feature.9 
These aspects of FND potentially make objective 
‘snapshot’ measures (eg, clinician- rated scales and 
objective performance tests) less reliable and valid. 
They also suggest that patient- rated outcomes may 
be particularly meaningful in this population.
A wide range of additional physical symptoms 
(eg, fatigue, pain, sleep disturbance, gastrointestinal 
and urological problems) are common in people 
with FND, typically associated with reduced quality 
of life and greater disability.10 11 More generally, 
elevated physical symptom burden is associated 
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box 1 search terms
Primary terms: ‘conversion disorder’ OR ‘psychogenic’ OR 
‘non*epileptic’ OR ‘hysteri*’ OR ‘functional neurological’ OR 
‘functional movement’ OR ‘functional motor’
Combined with AND:
Part 1: ‘outcome*’ OR 'measurement instrument' OR 
'assessment' OR ‘scale*’ OR ‘outcome measure*’ OR 
‘questionnaire’
Part 2: 'trial' OR 'treatment*' OR 'intervention' OR 'treatment 
outcome*' OR ‘randomi*ed’ OR ‘therap*’.
with significant disability, role impairments and high healthcare 
use.12 13 Many individuals with FND report significant psycho-
logical symptoms/comorbidity (eg, anxiety, depression and 
dissociation), potentially unhelpful coping behaviours and illness 
beliefs, and altered emotional processing, which are associated 
with symptom severity, poorer outcomes and diminished quality 
of life.10 11 14–23 These factors, therefore, may be particularly rele-
vant to psychosocial outcomes in FND.24 25
There is clearly a wide range of outcome domains relevant 
to FND, and a key challenge is to determine which are most 
important to capture. In evidence- based medicine, there has 
been an increasing emphasis on consistency in outcome measure-
ment and the Core Outcome Measures in Effectiveness Trials 
(COMET, http://www. comet- initiative. org/) initiative facilitates 
the development of core outcome measure sets across a range 
of physical and mental health disorders. The COMET collabo-
ration recommends five key outcome domains, including core 
physiological/clinical symptoms, life impact (ie, quality of life, 
functioning or participation and subjective health perception), 
resource use (health and social), adverse events and mortality. 
Another initiative, supported by the National Institutes of 
Health, involves development of ‘common data elements’, 
which currently includes core measures for neurological disor-
ders (https://www. nlm. nih. gov/ cde/ summary_ table_ 1. html).
An important step towards developing a core outcome measure 
set is to review measures currently used in outcome studies,26 
but there has been no previous review of outcome measures in 
FND. We aimed to systematically review the currently available 
FND- specific outcome measures and to identify those measures 
used most frequently in FND intervention studies to date. We 
sought to review the outcome domains and measures used in 
FND treatment research and their quality, not to evaluate the 
treatments, outcome data or methodologies used. Finally, we 
aimed to integrate these findings with conclusions derived 
during two international expert consensus meetings of the Func-
tional Neurological Disorder–Core Outcome Measures (FND- 
COM) group (http://www. comet- initiative. org/ studies/ details/ 
951), with the aim of developing recommendations for outcome 
measurement in future studies.
MeThOds
The systematic review was conducted in two parts to identify
1. Publications describing existing FND- specific outcome 
measures.
2. Randomised controlled trials (RCTs) and prospective inter-
vention studies in FND.
The Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) guidelines were followed.27
search strategy
PubMed (MEDLINE), Embase and PsycINFO were searched for 
both parts of the review. Trial registry websites (eg,  clinicaltrials. 
gov and  ISRTCN. com) were also searched to identify interven-
tion studies. The search terms are detailed in box 1. The terms 
were searched in the abstract, keyword and title fields, mapped 
to Medical Subject Headings. Reference lists were searched 
manually for additional sources. Members of the FND- COM 
group were consulted for additional studies.
eligibility criteria
Articles written in English and published in peer- reviewed jour-
nals between January 1965 and June 2019 were included. We 
included registered in progress trials, for part 2. Articles referring 
to core sensorimotor FND symptoms (including seizures) were 
included, whilst those referring to other less common symptoms 
(ie, speech and swallowing and cognitive) were excluded.5
For part 1, we included articles describing the psychometric 
evaluation of an outcome measure explicitly for FND. Instru-
ments designed for diagnosis of FND were excluded as these are 
not designed to measure change in FND symptoms over time. 
Measures assessing symptoms across bodily systems (ie, not 
exclusively neurological) and/or those validated in patients with 
mixed physical symptoms were excluded.
For part 2, studies were eligible if they prospectively measured 
outcomes of a specified intervention in patients with FND. 
Studies were excluded if the target samples included individuals 
with psychiatric diagnoses without FND or individuals with 
FND as a secondary or uncertain diagnosis. Case reports, case 
series and retrospective designs were excluded.
data extraction and management
Initial screening of the titles and abstracts was conducted by one 
author (SPi), to exclude those not meeting basic eligibility criteria 
(ie, duplicates, not FND). The remaining titles, abstracts and/or full 
texts were screened independently by the lead author (SPi) and a 
second independent rater (TRN, SPo, RCK and ABW). Disparities 
were resolved by discussion or by a third independent rater.
In part 1, the following were extracted: (1) lead author, (2) 
publication date, (3) name of instrument, (4) type of instrument 
(eg, self- report questionnaire and clinical evaluation), (5) content 
of measure, (6) validation sample and (7) measurement properties. 
For part 2, the data extracted were (1) the lead author, (2) publica-
tion date, (3) geographical location, (4) nature of intervention(s), 
(5) design (eg, parallel and cross- over), (6) details of blinding 
(ie, participants and intervention deliverer), (7) FND symptoms, 
(8) sample size, (9) timescale, (10) outcome measures and (11) 
measurement properties. The specific measurement properties 
(validity, reliability and responsiveness) that were systematically 
extracted (where available) are defined in online supplementary 
file 1.28–31
FNd-COM group consensus meetings
The findings of the reviews were discussed at two international 
consensus meetings (September 2017, Edinburgh, UK; September 
2018, Atlanta, USA) involving 43 members from 12 countries, 
all with expertise in FND treatment or outcome research. The 
members represented a range of relevant health professions 
(neurology, (neuro)psychiatry, (neuro)psychology, physiotherapy 
and occupational therapy) and patient representation.
resulTs
existing FNd-specific outcome measures
Five articles were eligible (online supplementary appendix 1 for 
the PRISMA diagram), which are summarised in table 1. Three 
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Table 1 Existing outcome measures developed for use in functional neurological disorder
study details Measure description of measure
Cianci et al (Italy)34 Rating scale for functional ‘psychogenic non- epileptic’ 
seizures (clinician- rated)
Motor phenomena (tremor/oscillation, tonic, clonic/jerking, 
hypermotor/agitation, atonic/akinetic and automatisms)
Associated features (incontinence, tongue- biting, drooling, eye 
closure, hyperventilation and lamenting/crying)
Responsiveness
13 body regions
Ratings: present/absent, severity, duration, global severity by 
phenomenon
Total phenomenology, total associated features and total 
seizure scores
Hinson et al
(USA)32
PMDRS (clinician- rated) Motor phenomena (rest tremor, action tremor, dystonia, chorea, 
bradykinesia, myoclonus, tics, athetosis, ballism and cerebellar 
incoordination)
Functions (gait and speech)
14 body regions
Ratings: present/absent, severity, duration, global severity and 
incapacitation by phenomenon/function (0–4 scale)
Total phenomenology, total function and total PMDRS score
Ijaz et al
(Pakistan)36
CDS- R (patient- rated) 40 items (phenomena): five factors identified (swallowing/
speech, motor, sensory, weakness/fatigue and mixed)
Ratings: 0–2 (not at all, sometimes and most of the time) for 
each item
CDS- R total scores (clinical cut- off score of 19)
Nielsen et al (UK)33 S- FMDRS (clinician- rated) Seven body regions
Two functions (speech and gait)
Ratings: presence/absence of abnormal movement, severity and 
duration (0–3 scale)
Total S- FMDRS score
Sarfraz and Ijaz
(Pakistan)35
CDS (patient- rated) 19 items (phenomena): three factors (disability, pain and 
seizures)
CDS, Conversion Disorder Scale; CDS- R, Conversion Disorder Scale—Revised; PMDRS, Psychogenic Movement Disorder Rating Scale; S- FMDRS, Simplified Functional Movement 
Disorders Rating Scale.
articles described clinician- rated scales, two assessing functional 
movement disorder (FMD) symptoms: Psychogenic Movement 
Disorder Rating Scale (PMDRS),32 Simplified Functional Move-
ment Disorder Rating Scale (S- FMDRS)33 and one clinician- rated 
measure for functional (ie, psychogenic non- epileptic/dissociative) 
seizures.34 Two patient- rated measures assessed a range of FND 
symptoms in children (Conversion Disorder Scale (CDS) and 
Conversion Disorder Scale—Revised (CDS- R)).35 36 There was no 
single outcome measure for use across FND symptom subtypes 
in adults and none designed specifically for functional weakness/
paralysis or sensory symptoms. The measurement properties of the 
scales are outlined in online supplementary file 2 and summarised 
as follows.
Validity
The content validity of the measures has not been confirmed 
according to established standards.28 30 Only two studies referred 
to consultation with independent experts during scale develop-
ment,35 36 and none reported consultation with patients. Regarding 
construct validity, exploratory factor analysis was conducted for 
both patient- reported measures.35 36 The CDS had three under-
lying factors (disability, pain and seizures) and the CDS- R had five 
factors (swallowing and speech, motor symptoms, sensory symp-
toms, weakness and fatigue, and mixed symptoms).
Criterion validity for new measures of FND symptoms is diffi-
cult to assess due to a lack of validated gold standards. However, 
moderate–strong correlations (r>0.3) with measures of similar 
or related constructs were noted for some scales, suggesting 
acceptable convergent validity.32–34 36 The CDS and CDS- R also 
differentiated patients with FND from healthy controls.35 36
Reliability
Inter- rater reliability (IRR) statistics for the clinician- rated scales 
were generally in an acceptable range (coefficients of >0.8 
for total scores), except for the seizure rating scale, which had 
slightly lower IRR (several coefficients of <0.7).34 The internal 
consistency of the patient- rated measures was satisfactory to 
good (Cronbach’s alpha values of >0.8 for total scores).35 36
Responsiveness
The PMDRS detected a significant change in patients’ scores 
between preintervention and postintervention.32 The S- FMDRS 
also displayed good sensitivity to change, with a large effect size 
(Cohen’s d=0.79) between post- treatment scores in an interven-
tion group compared with controls.33 Data on responsiveness 
were not reported for the other measures.
Limitations
While the studies indicated some sound measurement proper-
ties of these scales, there were limitations to the psychometric 
evaluations conducted, according to the recommended guide-
lines.28 30 31 None of the measures were evaluated in more than 
one study by independent research teams, although additional 
data on the measurement properties of the PMDRS have been 
provided in subsequent intervention studies. Validity data were 
variable and often incomplete, most importantly for content/
face validity. No study included confirmatory factor analysis 
or item response theory and Rasch analyses to assess construct 
validity.37 Similarly, none of the measures were validated cross- 
culturally, and there was limited evidence relating to ecological 
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Table 2 Primary outcome measures used across randomised controlled trials for FND subgroups
FNd symptoms Primary outcome measures
Seizures (k=15) Core symptoms
 ► Seizure frequency/occurrence (k=11)38–45 (S1 and S2) (Fobian NCT02801136).
Life impact
 ► SF-36/QoLIE-31 (k=1) (Hingray NCT02311829).
 ► WSAS (k=1).45
Other
 ► Treatment adherence/HCU (k=3) (S3 and S4) (Schommer NCT03329703).
Movement disorder 
(k=7)
Core symptoms
 ► PMDRS (k=4) or other FMD clinician rating scale (k=1) (S5–S9).
 ► CGI- I (clinician) (k=1) (S10).
Other
 ► Unspecified (k=1) (S11).
Paralysis/weakness 
(k=4)
Core symptoms
 ► Subjective symptom severity ratings (k=1) (S12) or CGI- I (patient) (k=1) (Nicholson ISRCTN51225587).
 ► Clinician- rated symptom severity (Chastan NCT01352910).
 ► Dynamometry (k=1) (S13).
Life impact
 ► Disability (SF-12, MRS, k=1) (S12).
Mixed motor 
symptoms (k=4)
Core symptoms
 ► CGI- I (k=1) (Koning- Tijssen NCT02589886).
Life impact
 ► SF-36 Physical Functioning Scale (k=1) (S14).
Other
 ► Unspecified (k=1) (S15).
Other mixed symptoms 
(k=10)
Core symptoms
 ► Clinician- rated symptom severity (k=3) (S16–S18)
 ► CGI- I (k=2, 1=clinician, 1=patient) (S19 and S20).
 ► SDQ-20 (k=1) (S19).
 ► Recovery (unspecified, k=1) (S21).
Life impact
 ► SF-36 (k=1) (S22).
 ► MRS (k=1) (S19).
Other
 ► Treatment adherence/HCU (k=1) (Bullock NCT02764476).
 ► Interoception/attention tasks (k=1) (S23).
References S1- S23 are available in Supplementary File 7
CGI- I, Clinical Global Impression–Improvement; FMD, functional movement disorder; FND, functional neurological disorder; HCU, healthcare use; k, number of studies; MRS, 
Modified Rankin Scale; PMDRS, Psychogenic Movement Disorder Rating Scale; QoLIE-31, Quality of Life In Epilepsy-31; SDQ-20, Somatoform Dissociation Questionnaire-20 item; 
SF-12, 12- Item Short Form Health Survey; SF-36, 36- Item Short Form Health Survey; WSAS, Work and Social Adjustment Scale.
validity. Sample sizes were relatively small for validations (ie, 
120 or less) and a priori sample size calculation or justification 
was omitted, except for one study which reported a large effect 
size (Cohen’s d=0.79) for comparison of control and interven-
tion groups.33 Only three studies included data from control 
groups.33 35 36 Bias was potentially present in most samples due 
to recruitment within specialist healthcare clinics and/or strin-
gent inclusion criteria. While all studies presented at least one 
appropriate measure of reliability, there were several omissions 
across studies and data were generally incomplete. For example, 
none of the articles provided statistics on test–retest reliability.
Outcome domains and measures in existing FNd treatment 
studies
Randomised controlled trials
Forty RCTs were identified (31=published and 9=ongoing or 
unpublished) (online supplementary appendix 2 for the PRISMA 
diagram). Online supplementary files 3 and 4 detail the study 
designs and outcome measures adopted. Table 2 summarises the 
primary outcome measures in these RCTs across FND symptom 
subtypes.38–45 Most RCTs focused on FND symptom change 
as the primary outcome measure (k=26). The most consistent 
primary outcome measure was functional seizure frequency; 
however, studies differed in how this was operationalised (eg, 
weekly or monthly seizure counts), and there was no single 
standardised way of recording the seizures (eg, patient seizure 
logs or clinical records). For FMD, the most common approach 
was a structured clinician- rated scale (eg, PMDRS), which can 
include standardised video protocols assessed by blind raters. 
Patient- rated symptom severity was often the primary outcome 
for functional limb weakness or mixed symptoms. The Clinical 
Global Impression–Improvement (CGI- I) scale46 was used as 
the primary outcome measure in five studies (clinician- rated=2, 
patient- rated=2 and unspecified=1). At least one of the Clinical 
Global Impression (CGI) scales (improvement and/or severity) 
was included as a primary or secondary outcome in 13 studies.
Ten RCTs included a measure of additional physical symptoms, 
with the Patient Health Questionnaire-15 (PHQ-15)47 (k=3) 
and Symptom Checklist-90 (SCL-90)48 somatic subscale (k=3) 
used in several studies. Twenty- eight RCTs included a measure 
of psychological symptoms (primary or secondary), most 
commonly depression and/or anxiety. Patient- rated measures 
included the Hospital Anxiety and Depression Scale (HADS, 
k=9),49 the Beck Depression Inventory (BDI or BDI- II, k=7)50 
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Table 3 Common outcome domains and measures in functional 
neurological disorder intervention studies
Outcome domain Commonly used measures
Core symptoms CGI- I: patient- rated=9, clinician- rated=7, 
both=4
Seizure frequency/remission=30
PMDRS=10
Other physical symptoms PHQ-15/extended PHQ-15*=7
SCL-90 Somatic Symptom Scale=6
Psychological symptoms Depression: BDI/BDI- II=12, HAM- D=13
Anxiety: BAI=8, HAM- A=7
Depression and anxiety: HADS=14
Life impact: quality of life/disability/
general functioning
SF-36=22, SF-12=3
QoLIE-31=7, QoLIE-10=2
WSAS=10
GAF=8
Health economics/cost–utility Healthcare resource use=20 (CSRI=4)
QALYs (SF-36/EQ- 5D- 5L)=3
Illness beliefs/attributions IPQ/modified IPQ=10
*Extended PHQ-15 (S29).
BAI, Beck Anxiety Inventory; BDI, Beck Depression Inventory; CGI- I, Clinical Global 
Impression–Improvement; CSRI, Client Service Receipt Inventory; DES, Dissociative 
Experiences Scale; GAF, Global Assesment of Functioning; HADS, Hospital Anxiety 
& Depression Scale; HAM- A, Hamilton Anxiety Rating Scale; HAM- D, Hamilton 
Depression Rating Scale; IPQ, Illness Perception Questionnaire; PHQ-15, Patient 
Health Questionnaire-15; PMDRS, Psychogenic Movement Disorder Rating Scale; 
QALY, quality- adjusted life years; QoLIE-10, Quality of Life in Epilepsy-10; QoLIE-31, 
Quality of Life in Epilepsy-31; SCL-90, Symptom Checklist-90; SF-12, 12- Item Short 
Form Health Survey; SF-36, 36- Item Short Form Health Survey; WSAS, Work and 
Social Adjustment Scale.
and the Beck Anxiety Inventory (BAI, k=5).51 The Hamilton 
Rating Scale for Depression (HAM- D, k=8)52 and the Hamilton 
Rating Scale for Anxiety (HAM- A, k=4)53 were commonly used 
clinician- rated measures. Psychological dissociation (eg, deper-
sonalisation, derealisation and amnesia) was measured with the 
Dissociative Experiences Scale54 in six trials.
Life impact was assessed in most studies. The Short Form 
Health Survey (SF) scales (12- Item Short Form Health 
Survey (SF-12)=3 and 36- Item Short Form Health Survey 
(SF-36)=1)55 56 were often included to measure health- related 
quality of life and/or disability. The Quality of Life in Epilepsy 
(QoLIE, k=6) scales (originally devised for epilepsy studies) 
were often used for patients with seizures.57 58 Disability was 
assessed specifically in 16 studies; however, while most studies 
used clinician- rated scales, there was little consistency in the 
scales adopted. Measures of general (ie, social and occupational) 
functioning were included in 12 studies, most often with the 
Work and Social Adjustment Scale (WSAS, k=6)59 or the Global 
Assessment of Functioning (GAF, k=5).60
Data for health economic/cost–utility analyses were also 
obtained in many trials. For example, healthcare resource use 
was monitored in a notable proportion (k=15). Four studies 
used a validated measure (Client Services Receipt Inventory, 
CSRI).[S24] A few studies provided data on quality- adjusted life 
years (QALYs) using the EQ- 5D- 5L.[S25]
Ten studies assessed illness perceptions or symptom attri-
butions often using study- specific questions or variants of the 
Illness Perception Questionnaire (IPQ, k=5).[S26–S28] Adverse 
events were reported in 11 trials.
Prospective cohort observational studies
Forty prospective observational treatment studies were iden-
tified (34=published and 6=ongoing/unpublished) (online 
supplementary appendix 2 and online supplementary file 5). 
The pattern of outcome measures was very similar to the RCTs. 
The most common outcome domain was core symptom change 
(k=33). Patient- rated functional seizure frequency was measured 
often (k=18), and clinician- rated scales were used to assess FMD 
symptoms (eg, PMDRS k=5 and S- FMDRS k=2) (k=11). Self- 
reported symptom severity was assessed in nine studies, often 
using the CGI- I scale (k=5). Clinician- rated CGI scales were 
used in a small proportion of studies (k=3).
Additional physical (k=6) and psychological (k=21) symp-
toms were commonly assessed. The PHQ-15 was the most 
frequently used measure of additional physical symptoms (k=4). 
Common measures of psychological symptoms included the 
HADS (k=5), the BAI, BDI (k=8), the HAM- D (k=5) and/or 
the HAM- A (k=3).
In terms of life impact, quality of life and disability were 
measured in 19 studies, with the SF-36 being the most consis-
tently adopted measure (k=11). Thirteen studies included 
measures of general functioning, including the WSAS (k=4) and 
GAF (k=3). A proportion of studies (k=7) monitored healthcare 
resource use or included other measures yielding data for health 
economic analyses. Illness beliefs were assessed in eight studies, 
again with the IPQ (or revised versions) in the majority (k=5). 
Three studies reported adverse events.
Measurement properties of outcome measures used in FNd 
intervention studies
The review identified several outcome domains and measures 
often included in FND treatment research (table 3). Available 
psychometric data detailing the measurement properties of these 
measures were extracted (online supplementary file 6).
Core symptoms
Clinical Global Impression–Improvement Scale
Few studies reported data pertaining to the validity or reli-
ability of the CGI- I scale in FND samples. In one study, 
patient- rated CGI- I scores were significantly predicted by post- 
treatment change in Health of the Nation Outcomes Scale 
scores (p=0.033).[S30] However, another noted no significant 
associations between clinician- rated CGI- I and SF-36 or HADS 
scores,[S31] suggesting weak convergent validity with these 
outcome domains. Only one study examined reliability, noting 
moderate IRR between clinician- rated CGI- I and CGI- severity 
scores (kappa=0.65).[S10]
Some data suggested that the CGI- I scale is sensitive to change 
in this population. Post- treatment improvements were reported 
in most studies. The proportion of patients reporting improve-
ment after an intervention was 60%–96% in 6/9 studies.[S9, 
S15, S30, S32–S34] In two studies, 30%–48% of the active 
intervention groups reported improvements,[S10, S20] whereas 
in one study, only average scores were reported.[S7] Average 
reported patient- rated and clinician- rated CGI- I scores were 
in the minimally to much improved range.[S7, S31, S33, S35] 
Significant treatment effects in patient- rated and clinician- rated 
CGI- I scores were observed,[43, S2, S19, S20] although not 
consistently.[42, S6, S10] Effect sizes varied from small to large.
[43, S2, S10, S20] These findings suggest that the CGI- I scale has 
adequate responsiveness in patients with FND, but more data are 
needed for different symptom types and treatment modalities.
Seizure frequency/freedom
There were no data available on reliability for seizure outcomes 
and few studies reported data relevant to validity in these FND 
samples. De Barros et al noted significant correlations between 
post- treatment seizure frequency and HAM- D, HAM- A and alex-
ithymia scores (p<0.05).[S36] Furthermore, Kuyk et al observed 
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a significant negative correlation between post- treatment seizure 
frequency and SF-36 energy–vitality scores (p<0.05).[S37] 
Seizure- free patients showed significantly greater improvement 
on several SF-36 subscales (mental health, energy–vitality and 
pain), BDI and STAI (anxiety) scores, relative to patients who 
were not seizure- free (p<0.05).
Post- treatment decreases in seizure frequency or increases in 
seizure freedom were observed in a proportion of patients across 
all studies. A number of studies reported statistically significant 
treatment effects on seizure frequency [39, 40, 42–44, S2, S4, 
S36–S44] or seizure freedom.[38, S45] Effect sizes were gener-
ally small–medium.[40, 42, S2, S4] Future studies should stan-
dardise the methods of logging/comparing seizure outcomes to 
provide more comparable data.
Psychogenic Movement Disorder Rating Scale
Dreissen et al reported adequate IRR for the PMDRS (average 
intraclass correlation coefficient=0.76),[S10] which is lower than 
the original values presented by Hinson et al (0.87–0.89),32 but 
both are in an acceptable range. Regarding validity, Taib et al[S7] 
observed significant negative correlations between PMDRS total 
and SF-36 physical role scores (r=−0.77, p=0.0002), and between 
PMDRS total and SF-36 general health scores (r=−0.67, p=0.02). 
PMDRS total scores also correlated positively with CGI severity 
(r=0.88, p=0.001). Similarly, the original validation study noted a 
positive correlation between CGI and total PMDRS scores.32 These 
relationships suggest good convergent validity. Seven out of 10 
studies reported significant treatment effects for the PMDRS,[32, 
S5, S7, S32, S46–S48] and one noted a significant improvement 
in a placebo arm but not for the active intervention.[S8] Together, 
these findings suggest that the PMDRS shows adequate sensitivity 
to change in people with FMD.
Other physical symptoms
The two most common measures of additional physical symp-
toms were the PHQ-15 and the SCL-90 somatic symptoms scale. 
There were no data available regarding the reliability or validity 
of these measures in these FND intervention studies.
Patient Health Questionnaire-15
Five studies presented post- treatment data for the PHQ-15. Four 
studies reported significant reductions in post- treatment scores.
[S5, S20, S30, S49] Williams et al22 also noted a decline in symp-
toms, but the statistical significance did not withstand correction 
for multiple testing (p=0.03). One study reported a medium 
effect size (d=0.53).[S30] Together, these findings suggest that 
the PHQ-15 shows good responsiveness across FND subgroups.
Symptom Checklist-90
Five studies reported outcomes on the SCL-90 somatic scale, 
with two observing significant improvements[S2, S40] and one 
reporting a large effect size.[S2] The responsiveness of this scale 
in FND samples requires further examination.
Psychological symptoms
The HADS, BDI (I or II) and BAI were common patient- rated 
outcome measures for anxiety and depression, and the HAM- D 
and HAM- A were often used as clinician- rated measures. There 
were no data regarding reliability for these measures in these 
FND samples.
Hospital Anxiety and Depression Scale
Conwill et al[S31] reported no significant association between 
HADS and CGI- I (clinician) scores, suggesting poor convergent 
validity with core symptom change. Outcome data for the HADS 
were provided in 12 studies; however, significant treatment 
effects were only reported in four (33%) and reported effect 
sizes were variable.[43, S30, S39, S44]
Beck Depression Inventory & Beck Anxiety Inventory (BDI and BAI)
There were no data on the validity of the BDI/BAI in these FND 
samples. Nine studies reported outcomes for the BDI (I or II), 
with six (67%) reporting significant treatment effects.[39, S2, 
S19, S40, S43, S50] Large effect sizes were reported in two 
studies.[39, S2] Six studies provided outcome data for the BAI, 
with significant treatment effects observed in four[32, S2, S5, 
S46] and a large effect size in one.[S2] One study reported a 
significant improvement in two treatment arms.[S6]
Hamilton Anxiety Rating Scale and Hamilton Depression Rating 
Scale
HAM- A and HAM- D scores positively correlated with post- 
treatment seizure frequency in one study.[S36] Demartini et 
al[S32] found that HAM- A and HAM- D scores were signifi-
cantly higher in patients with FND relative to healthy controls at 
baseline, suggesting adequate known- groups validity.
Three of five studies reporting outcome data for HAM- A 
reported significant treatment effects.[38, S36, S44] Two studies 
showed non- significant trends for improvement following 
treatment.[S8, S32] Thirteen studies reported post- treatment 
outcomes for HAM- D scores, with six reporting significant 
effects.[32, S2, S5, S36, S44, S46] Vizcarra et al[S8] noted a 
significant improvement in a placebo arm but not an interven-
tion arm, whereas Kompoliti et al[S6] noted significant improve-
ments in two treatment arms. Effect sizes were moderate–large 
(d=0.71–1.8).[S2, S36]
life impact
Short Form Health Survey-36 & Short Form Health Survey-12 (SF-36 
and SF-12)
The SF scales were the most consistently used of all measures 
in these studies (most often SF-36). There were no data avail-
able on their reliability in the FND samples, but three studies 
examined correlations with other relevant measures. Conwill et 
al[S31] found no significant associations between SF-36 scores 
and CGI- I (clinician) ratings. However, Kuyk et al[S37] noted 
significantly greater improvements on SF-36 domains (mental 
health, energy–vitality and pain) for seizure- free patients at 
follow- up. Williams et al22 observed a significant positive 
correlation between post- treatment SF-36 mental health compo-
nent scores and emotional processing improvements (p<0.008).
Significant treatment effects were observed on domains of 
the SF-36/SF-12 in 14/18 studies presenting outcome data.[22, 
S11, S15, S19, S20, S22, S31, S32, S34, S36, S37, S42, S49, 
S51] Effect sizes were generally moderate.[22, S15, S34, S36] 
Significant effects were most often observed for mental health 
(k=9), emotional role (k=4), general health (k=4), social func-
tion (k=4) and physical function (k=4). Several studies showed 
differences in the physical component (k=3), physical role (k=3) 
and energy/vitality (k=3) domains.
Quality of Life in Epilepsy-31 & Quality of Life in Epilepsy-10 
(QoLIE-31 and QoLIE-10)
No data on validity or reliability were available for the QoLIE 
scales in these functional seizure samples. However, post- 
treatment outcome data were available in seven studies. Four 
reported significant treatment effects [39, S2, S4, S40] and one 
reported a non- significant trend towards improvement.[S52] 
Effects sizes were moderate–large.[39, S2, S4]
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Work and Social Adjustment Scale
The WSAS was included in 10 studies. There were no data on 
validity and reliability of the WSAS in the FND samples included. 
Of eight studies with outcome data, three reported significant 
treatment effects.[45, S34, S39] Reported effect sizes were small.
[S15, S45] The measurement properties of the WSAS in FND 
require further examination.
Global Assessment of Functioning
In the five FND intervention studies providing data on the GAF, 
there were no details on its validity or reliability. Four studies, 
however, showed significant treatment effects.[32, S2, S40, S53] 
LaFrance et al[S2] reported large effect sizes (d=1.2–1.8).
health economics and cost–utility
Healthcare resource use
A proportion of studies reported data on healthcare resource 
use. The most common way to measure this was to obtain 
a frequency count of healthcare contacts (eg, total healthcare 
contacts, emergency department, inpatient hospital days, outpa-
tient contacts and mental health contacts), either by self- report 
or obtained from clinical records. No data were available for 
validity and reliability and few significant differences were noted 
following treatment in these FND samples.
In patients with functional seizures, significant post- treatment 
reductions in emergency department visits and overall healthcare 
use [S2, S41] and greater probability of contact with a mental health 
professional [S3] were reported in a few studies. In patients with 
mixed FND symptoms, Aybek et al[S51] observed reduced postin-
tervention medical follow- up, and Hubschmid et al[S19] reported 
fewer postintervention inpatient hospital days. Greater consistency 
is needed in healthcare use measurement in future studies.
Quality-adjusted life years
A minority of studies reported data on QALYs (k=3). Nielsen et 
al[S15, S34] calculated QALY utility scores from the EQ- 5D- 5L, 
reporting post- treatment gains of 0.125 and 0.08. One study 
reported the average cost per QALY as £12 087.[S15] Reuber 
and colleagues reported QALY data derived from the SF-36, 
reporting post- treatment gains of 0.04 and an average cost per 
QALY of £5328.[S49] More data are needed on QALYs and their 
associated costs for different FND treatments.
Illness perceptions/attributions
Illness perceptions and attributions were measured often with 
the IPQ or revised versions. There was no evidence of the reli-
ability or validity of the IPQ in these FND samples. Demartini 
et al noted that IPQ- Revised (IPQ- R) scores at baseline were not 
predictive of patient- rated CGI- I outcomes (p=0.77).[S30]
All seven studies providing post- treatment data on the IPQ 
(or Brief- IPQ and IPQ- R) reported statistically significant post- 
treatment improvements. Some studies reported post- treatment 
reductions in composite scores.[22, S15, S45] Other studies 
reported significant improvements on individual items, including 
beliefs about illness permanence (timeline, k=3), perceived nega-
tive consequences (k=2) and level of concern (k=2). Individual 
studies also reported significant differences in illness under-
standing, emotional representations, physical attributions, psycho-
logical attributions and belief in possible cure/management.
Several studies explored illness beliefs with study- specific 
methods. In patients with functional seizures, belief that the 
seizures could be helped (OR=3.9, p=0.003), subjective control 
(OR=3.3, p=0.021) and an internal locus of control (OR=7.5, 
p<0.001) significantly predicted seizure freedom at follow- up.
[S54] Significant post- treatment changes in beliefs relating to 
functional seizures have been noted, including perceived control, 
being bothered by the seizures, perceived impact, ability to avoid 
triggers and perceived understanding.[39, 45, S45] Additional 
data are needed to explore the importance of these changes for 
patients’ outcomes.
FNd-COM CONseNsus OPINION
Key points that emerged from the FND- COM group meetings 
and subsequent interchanges were as follows:
General issues
 ► Challenges for FND outcome measurement include the 
temporal variability of symptoms and the impact of atten-
tion, beliefs and expectations.
 ► Patient- rated outcome measures are important when 
assessing outcomes in this population.
 ► Discrepancies between objective and patient- rated outcomes 
may provide insights into the mechanisms underlying symp-
toms and treatment responses.
Measuring FNd symptom change
 ► There are few validated outcome measures for FND symp-
toms across symptom types.
 ► There was some dissatisfaction with the PMDRS among the 
FND- COM members. Key limitations of this scale have been 
outlined elsewhere.33
 ► Of the clinician- rated scales for FMDs, the S- FMDRS was 
preferred by the FND- COM group due its ease of adminis-
tration and lack of requirement for expertise in movement 
disorder phenomenology. However, this measure currently 
is not used widely, possibly due to time constraints, cost and 
the limitations of snapshot clinician- rated measures.
 ► Assessing the criterion validity of new FND- specific 
symptom measures is challenging due to a lack of existing 
‘gold standard(s)’.
 ► An individualised approach could be considered, whereby 
patients select the most troublesome symptoms and then use 
an individualised scale to assess change on these difficulties, 
or in which patient- specific goals are identified and progress 
towards them is subsequently monitored (eg, Psychological 
Outcome Profiles (PSYCHLOPS), Goal Attainment Scaling).
[S55, S56]
Additional outcome domains
 ► Measures of the impact of FND (ie, quality of life, disa-
bility, functioning and psychological distress) are important 
domains as they are relevant across all symptom types.
 ► Existing, generic outcome measures, known to be reliable 
and valid in related populations, can be used for adjunctive 
key outcome domains in FND (eg, quality of life, additional 
physical symptoms and global functioning).
 ► Illness beliefs and attributions may be important mediators 
of treatment response and/or might represent a common 
domain of change across different treatments.
dIsCussION
We aimed to identify FND- specific outcome measures, describe 
the outcome domains and measures most commonly included 
in previous FND intervention studies, integrate these findings 
with FND- COM group expert opinion and present preliminary 
recommendations for outcome measurement in future studies.
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existing FNd-specific outcome measures
Only five FND- specific outcome measures were eligible: three 
clinician- rated scales32–34 and two self- report measures.35 36 
There were no measures specifically for functional limb weakness 
or sensory symptoms. Importantly, there is no single outcome 
measure suitable for use across all adult FND symptom types.
Of the identified scales, content validity was not established 
rigorously and the validation studies were limited by homoge-
neous or unrepresentative samples, cultural specificity and a lack 
of evidence of ecological validity. Data on responsiveness were 
not available for all scales.34–36 Due to the limited evidence for 
satisfactory measurement properties of the scales identified,28 30 it 
is not possible to recommend their use as core outcome measures 
at present.
There is a clear absence of FND- specific outcome measures 
to capture the full spectrum of FND symptoms. It is therefore 
unclear whether any single measure could adequately capture all 
relevant domains for the FND population, given its semiologic 
and symptomatic heterogeneity. Furthermore, it is possible that 
FND- specific outcome measures may be unnecessary and that 
existing measures used in other related disorders are valid and 
reliable for measuring outcomes in FND.
Outcome domains and measures in previous FNd intervention 
studies
Outcome domains measured commonly in previous intervention 
studies included core FND symptoms, other physical symptoms, 
psychological symptoms, life impact (quality of life, disability 
and general functioning), and health economics or cost–utility 
(healthcare resource use and QALYs). These domains and the 
associated measurement tools are discussed further.
Core FND symptom change
The CGI scales and patient- reported seizure frequency or freedom 
(functional seizures) were the most consistently used measures of 
symptom change. The main advantage of the CGI- I scale is that 
it can be used across the full range of FND symptoms, allowing 
for direct comparisons of treatments across diverse presenta-
tions. It is brief and simple to administer and can assess specific 
symptoms or global clinical status. However, there are scarce 
data on the validity and reliability of this scale in FND samples, 
and mixed findings regarding its responsiveness. Another limita-
tion is the lack of evidence for inter- rater reliability of the CGI. 
Furthermore, the scale is ordinal in nature (ie, scores are relative 
to baseline state only) and does not provide an absolute quantifi-
cation of the utility of an intervention. There are data from other 
relevant patient populations suggesting acceptable measurement 
properties,[S57- S61] but future studies should examine further 
the properties of this scale in FND samples, including correla-
tions between patient and clinician ratings. A modified version 
of the CGI for use in FND could also be considered, similarly to 
its use in other disorders.[S62, S63]
The assessment of seizure frequency and/or freedom was the 
most common outcome for studies involving functional seizures. 
However, there was variability in how these were defined and 
a lack of data on their reliability and validity. Some preliminary 
evidence of convergent validity with other outcome domains was 
available. Importantly, improvements in seizure outcomes were 
observed consistently, with many studies reporting significant 
treatment effects. A standardised approach to operationalising 
seizure outcomes would be beneficial for future studies.[S64] It 
may be relevant to monitor duration/severity and specific seizure 
symptoms, as well as event frequency.
Clinician- rated scales were adopted most often for FMD. 
The PMDRS was used frequently, and findings suggested some 
sound measurement properties. However, the face validity of the 
measure has not been examined sufficiently and doubts have been 
raised about its practical utility, along with other limitations.33
Other physical symptoms
Additional physical symptoms were often measured in previous 
studies. The FND- COM group agreed that these symptoms are 
important outcomes for patients with FND, particularly pain 
and fatigue, which are prevalent and impactful. The two most 
common measures of additional physical symptoms (PHQ-15 
and SCL-90 somatic scale) lacked evidence of reliability and 
validity in studies of FND samples. Responsiveness was superior 
for the PHQ-15; this measure is brief and it has been validated 
across a wide range of physical and mental health diagnoses in 
various clinical and cultural settings.[47, S65- S68] The PHQ-15, 
therefore, is a potentially useful measure, but more data on its 
measurement properties are needed in FND. Extended versions 
of the PHQ-15 [S29] can also be considered in future research.
Psychological symptoms
Many studies included one or more measures of psychological 
symptoms, most often depression and/or anxiety, measured 
by the HADS or BDI and BAI (patient- rated) or HAM- A and 
HAM- D (clinician- rated).
There are several advantages of using the HADS, including 
its brevity, combined anxiety and depression subscales in a 
single measure, and the omission of physical manifestations, 
reducing the likelihood of confounding physical with psycho-
logical symptoms. The measurement properties of the HADS in 
FND samples are not well described and more data are needed. 
However, the HADS has shown good measurement properties 
across other physical and mental health diagnoses and cross- 
culturally.[S69- S74]
Evidence for the reliability and validity of the BDI (BDI- II) 
and BAI in FND was lacking in the FND intervention studies 
reviewed. Responsiveness was stronger for these measures, but 
interpretation is potentially hindered by the inclusion of phys-
ical symptoms in these scales (eg, fatigue, sleep disturbance and 
tremor). Nevertheless, both the BAI and BDI/BDI- II have also 
been validated in a range of clinical and non- clinical popula-
tions, and across cultures.[S75- S79] The HAM- A and HAM- D 
seem to be the most useful clinician- rated measures of psycho-
logical symptoms. Although reliability and validity have not been 
rigorously examined in FND samples, these scales show prelim-
inary evidence of adequate responsiveness.
Life impact
The most common measure of life impact was the SF-36. This 
measure has the advantage of assessing patients’ subjective 
perceptions of overall health status, aspects of disability, and 
physical and mental health in a single measure, and can also be 
used for the derivation of QALYs. A key benefit of the SF-36 
for use in FND is its multidimensional nature; it is possible to 
examine outcomes on eight specific subscales, depending on 
the goals and modality of a given treatment. Again, there was a 
paucity of reliability and validity data in FND samples, but there 
is considerable evidence for responsiveness, with most studies 
reporting significant treatment effects on at least one SF-36 
domain. The SF-36 has also been well- validated across clinical 
populations and cultures.[S80- S82] The QoLIE scales serve a 
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Table 4 Recommendations for outcome measurement in FND
Outcome domain recommended measures
supplementary/alternative 
measures
Core FND symptoms  ► CGI- I patient (+/-clinician, 
+/-carer).
 ► Seizure frequency, 
prospective daily seizure log 
(for seizures).
 ► S- FMDRS or PMDRS (for 
FMD).
Other physical 
symptoms
 ► PHQ-15.  ► Extended PHQ-15.
 ► SCL-90.
Psychological symptoms  ► HADS
or
 ► BDI/BDI- II+BAI.
 ► HAM- D+HAM- A.
Life impact Quality of Life
 ► SF-36.
And/or
General (social/occupational) 
functioning
 ► WSAS.
 ► QoLIE-31/10 (for seizures).
 ► GAF.
Health economics/
cost–utility
Healthcare resource use
 ► Healthcare contacts (total, 
inpatient admissions, 
inpatient days, ED/
outpatient visits).
 ► CSRI.
 ► Scale validated for QALY 
conversion (EQ- 5D- 5L or 
SF-36).
AEs AEs, SAEs and mortality.
AE, adverse event; BAI, Beck Anxiety Inventory; BDI, Beck Depression inventory; CGI- I, 
Clinical Global Impression–Improvement; CSRI, Client Service Receipt Inventory; ED, 
emergency department; FMD, functional movement disorder; FND, functional neurological 
disorder; GAF, Global Assessment of Functioning; HADS, Hospital Anxiety Depression Scale; 
HAM- A, Hamilton Rating Scale for Anxiety; HAM- D, Hamilton Rating Scale for Depression; 
PHQ-15, Patient Health Questionnaire-15; PMDRS, Psychogenic Movement Disorder Rating 
Scale; QALY, quality- adjusted life years; QoLIE-10, Quality of Life in Epilepsy-10; QoLIE-31, 
Quality of Life in Epilepsy-31; SAE, serious adverse event; SCL-90, Symptom Checklist-90; SF-
36, Short Form Health Survey-36; S- FMDRS, Simplified Functional Movement Disorder Rating 
Scale; WSAS, Work and Social Adjustment Scale.
similar purpose in functional seizures, but more data are needed 
on the measurement properties in FND samples.
Additional measures of life impact include measures of general 
(social and occupational) functioning. The WSAS is often used 
to capture patient- reported general functioning and the GAF for 
clinician ratings. No evidence is available for the reliability or 
validity of either scale in FND samples. The responsiveness of 
the GAF appeared slightly stronger in the studies presented here.
Health economics and cost–utility
Health economic data were primarily derived from healthcare 
resource use frequency, with the CSRI or study- specific questions 
about healthcare contacts being the most common methods. The 
CSRI was developed in the UK, so it requires adaptation to local 
regions and is a relatively lengthy measure to administer; there-
fore, it is unlikely to be appropriate for widespread international 
use. Instead, specific questions about healthcare contacts (eg, 
emergency department or outpatient visits, inpatient hospital 
admissions and inpatient days) appear to be more generalisable 
methods. The EQ- 5D- 5L and SF-36 allow the derivation of 
QALYs and associated costs.[S83, S84] Future research is needed 
to compare the relative cost–utility of treatment modalities for 
different subgroups of patients with FND.
Illness perceptions/symptom attributions
Illness perceptions/beliefs were noted by the FND- COM group 
as also important to measure in FND treatment studies, as they 
might mediate change across different treatment modalities and 
symptom types. Of note, 100% of studies including a version of 
the IPQ noted significant treatment effects on composite IPQ 
scores or specific items. The original IPQ is relatively lengthy, 
but the B- IPQ or IPQ- R could be adopted (or modified) to better 
assess FND- relevant cognitions (eg, acceptance/understanding of 
the diagnosis, beliefs about causation and subjective control).
FNd-COM recommendations for outcome measurement in 
FNd
In the absence of rigorously validated, widely endorsed FND- 
specific outcome measures, we recommend an interim approach 
involving the assessment of core outcome domains with existing 
patient- rated measures that are valid, reliable and sensitive 
to change in FND or other relevant populations. The core 
domains and recommended measures are detailed in table 4, 
alongside additional supplementary patient- rated or clinician- 
rated measures. We recommend that these measures (or a 
subset) be assessed in future intervention research in adult FND 
populations.
There are similarities between the domains identified here 
and those described in recommendations for other related 
disorders (eg, chronic pain, fibromyalgia, complex regional 
pain syndrome and somatic symptom disorders).[S85- S89] The 
outcome domains and measures recommended here could be 
supplemented with additional tools, depending on the specific 
intervention and patient characteristics within individual studies. 
We also acknowledge that adaptations to these recommenda-
tions might be necessary due to cultural/context- specific factors. 
Furthermore, cost considerations may affect the use of the 
recommended measures, as some are licensed.
limitations
This article had some limitations. Articles not written in English 
were excluded. Future research on outcome measurement in 
FND should aim to examine cultural variation in practices, and 
outcome measures should be validated across cultural contexts. 
The focus of this article was on identifying and evaluating 
outcome measures specifically, so we did not conduct a quality 
appraisal of the methods used to assess the effectiveness and effi-
cacy of the interventions, nor did we evaluate the quality and 
significance of the outcome data in relation to the treatment 
modalities tested.
Future directions
This review highlighted several directions for future research 
and development. First, FND experts should convene to discuss 
further the need for new FND- specific outcome measures for 
use across all symptom types and additional tools for individual 
symptom types. Additional measures could include patient- 
rated, clinician- rated, caregiver- rated and/or objective measures. 
If deemed appropriate, the development and validation of such 
scales should be prioritised. Consideration of content and face 
validity should be given during the design and development of 
any new scales. Second, future FND intervention studies should 
aim to present data on the measurement properties of the 
outcome measures included (where possible), to strengthen the 
evidence base for the use of specific measures in FND. Outcome 
measures that are used frequently (eg, seizure frequency, SF-36 
and PMDRS) should undergo more extensive psychometric eval-
uation, where feasible, in larger samples of patients with FND, 
ideally across different cultures.
Future research may explore additional avenues for outcome 
measurement in FND, such as the use of objective/performance- 
based measures (eg, actigraphy and 5 m walk test), or person-
alised symptom rating or goal attainment scales. Discrepancies 
between patient- rated and objective/clinician- rated measures 
may provide important insights into mechanisms underlying 
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symptoms or therapeutic change. Additional psychological 
domains that could be relevant for future investigation include 
illness beliefs, psychological dissociation (eg, depersonalisation 
and derealisation) and aspects of emotional processing (eg, 
stress reactivity and alexithymia). It will also be important to 
explore which outcome domains and measures are most relevant 
for additional functional neurological symptoms not covered in 
this review, such as cognitive (eg, consciousness and memory), 
speech and swallowing symptoms.
An important direction for further research is to examine the 
perspectives of patients, carers and other relevant stakeholders 
on outcome measurement in FND, particularly exploring views 
on the relative merits of subjective and objective measures. Addi-
tional work is needed to develop recommendations for outcome 
measurement in children with FND, given that many of the 
recommended measures may not be validated or relevant for 
younger patients.
CONClusIONs
There is a need for greater consistency in outcome measurement 
in FND research. At present, we recommend an interim set of 
outcome measures to routinely assess core outcome domains, 
including core FND symptom change, other physical and psycho-
logical symptoms, life impact, health economics/cost–utility and 
adverse events. These recommendations could be supplemented 
with additional measures as appropriate to individual studies. 
Further research is needed to provide more extensive psycho-
metric evaluation of outcome measures for FND and to explore 
the views of patients, carers and other stakeholders on opti-
mising outcome measurement in this disorder.
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